Navigation Links
Valeant Pharmaceuticals Responds to Cephalon Board's Letter
Date:4/21/2011

nal specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

Certain statements made in this press release may constitute forward-looking statements of Valeant, including, but not limited to, statements regarding our offer to purchase Cephalon, financing related to the proposed transaction, our consent solicitation process or our intention to commence a tender offer, our opportunities and our plans should we acquire Cephalon, the effect of the proposed transaction on financial results, and certain financial projections.  Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions.  These statements are based upon the current expectations and beliefs of management of Valeant and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Valeant's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and Canadian Securities Administrators ("CSA") and other risks and uncertainties as discussed from time to time in Valeant's filings with the SEC and the CSA, which disclosures are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements.  Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press r
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
2. Regulatory Update - GSK and Valeant Respond to FDA on ezogabine
3. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
4. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
5. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
6. Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
7. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
8. GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
9. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
10. Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.
11. Valeant Announces Pricing of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... 8 Mylan Inc. (Nasdaq: MYL ) today announced ... and license agreements with Wyeth, now part of Pfizer, relating ... 75 mg and 150 mg, the generic version of Wyeth,s ... Pursuant to the license agreement, Mylan will be granted a ...
... , BEVERLY ... pioneering medical opiate detoxification procedure, offers one of the ... technology to treat dependencies to Zolpidem, a prescription medication widely used ... including Ambien and Edluar. The Waismann Method of ...
Cached Medicine Technology:Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R) 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... quickly add weight and length may be showing a genetic ... In adults, certain genes have been linked to increased body ... in fat and lean muscle, the researchers said. At ... taller. By ages 2 and 3, however, these genes were ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter , ... on Monday officially tightened guidelines for health workers treating Ebola ... and use of a respirator at all times. The ... the tougher rules after two Dallas nurses contracted Ebola while ... States, Liberian national Thomas Eric Duncan. Nina Pham is currently ...
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... , NEWPORT, Ky., June 4 Xanodyne Pharmaceuticals, Inc. ... been named to the position of President and Chief ... Company,s Board of Directors. In addition to Mr. Valentino,s ... led by MPM Capital. Current investors, participation also included; ...
... PARK, Calif., June 4 XTENT, Inc. (Nasdaq: ... from the United States Food and Drug Administration (FDA) for ... pivotal clinical program, composed of two pivotal trials called CUSTOM ... the United States of its Custom NX(R) Drug Eluting ...
... Cryobank , a leader in reproductive tissue banking, announced ... Reproductive Medicine Associates (RMA) of New ... collection center will provide fertility preservation services to patients in ... worldwide for outstanding donor semen services, California Cryobank also provides ...
... ... add new clinical rotations in obstetrics and gynecology at the Center for Haitian Studies ... ... University School of Medicine is pleased to announce it will add new clinical rotations ...
... ... Pediatric Gastroenterology Department published results from a promising yearlong study conducted ... reminder system to keep them taking critical medication on schedule. By ... only 2 patients experienced a rejection episode versus 12 patients prior ...
... ... Members for their service and selfless acts of courage that help make the IMD one ... ... District (IMD), the nation’s largest urban medical district, recognized its honored District Security Group (DSG) ...
Cached Medicine News:Health News:Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing 2Health News:XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration 2Health News:XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration 3Health News:Leading Sperm Bank Expands Fertility Preservation Services to the Big Apple 2Health News:Ross University School of Medicine Expands Clinical Rotations in Miami 2Health News:Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 2Health News:Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 3Health News:Illinois Medical District Recognizes Officers of its District Security Group 2
... The Accuris minimally invasive uni-compartmental knee ... field of orthopedic surgery. This procedure provides ... arthritis of the knee.,Arthritis of the knee ... function, reduction in quality of life and ...
... most total knee manufacturers focus attention on ... is instrumentation. The Profix Total Knee System ... total knee implant system and the tools ... Whiteside, M.D., widely recognized for innovation in ...
... MJS anatomic knee system ... durability, minimize polyethylene wear ... to minimize contact stress ... to achieve a well ...
... MJS™ Posterior Stabilized knee ... durability, minimize polyethylene wear between ... minimize contact stress associated with ... a well balanced knee with ...
Medicine Products: